Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset the ATLANTIS study: A randomized controlled trial

Wayne M. Clark, Stanley Wissman, Gregory W. Albers, Jack H. Jhamandas, Kenneth P. Madden, Scott Hamilton

Research output: Contribution to journalArticlepeer-review

1000 Scopus citations

Fingerprint

Dive into the research topics of 'Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset the ATLANTIS study: A randomized controlled trial'. Together they form a unique fingerprint.

Medicine & Life Sciences